ZOETIS (ZTS) Stock News

Zoetis (NYSE:ZTS) received a U.S. FDA Emergency Use Authorization (EUA) for Simparica Trio (sarolaner, moxidectin, pyrantel) to treat infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. The EUA applies only for the duration of the federal emergency declaration and does not constitute full approval for this use.

Simparica Trio remains FDA‑approved for broad parasite protection in dogs, including heartworm, multiple tick species, fleas, roundworms, hookworms and flea‑transmitted tapeworm. Zoetis also highlights Dectomax/Dectomax‑CA1, which hold conditional approval and EUA-based uses against New World screwworm in several livestock species, with specified withdrawal periods and species restrictions.

Zoetis (NYSE: ZTS) appointed James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created dual role, he will lead global finance, including capital allocation, financial strategy, reporting, controls and investor engagement, and oversee Global Manufacturing and Supply to drive operational execution.

With his appointment, current CFO Wetteny Joseph will become Special Advisor to the CEO on financial matters from August 17, 2026 until early 2027 to support a smooth transition. Saccaro previously served as CFO of GE HealthCare and held senior leadership roles over two decades at Baxter, including Executive Vice President and CFO and leadership of business development for its $5 billion Medication Delivery unit.

Zoetis (NYSE:ZTS) reported second quarter 2026 revenue of $2.468 billion, essentially flat year over year and down 1% on an organic operational basis. Net income was $691 million, or $1.65 per diluted share, down 5% and up 1%, respectively, on a reported basis.

Adjusted net income was $781 million and adjusted diluted EPS $1.87, down 1% and up 5% on a reported basis, and down 2% and up 4% on an organic operational basis. U.S. revenue declined 7% to $1.3 billion, driven by an 11% drop in companion animal sales, while livestock grew 23%. International revenue rose 8% to $1.2 billion, with 6% organic growth across companion animal and livestock.

Zoetis updated 2026 guidance to revenue of $9.120–$9.320 billion (organic operational revenue growth of (3)% to (1)%) and adjusted diluted EPS of $6.15–$6.25, with adjusted net income organic operational growth of (9)% to (5)%. The company also highlighted multiple new product approvals, expanded diagnostics capabilities, and the acquisition of VitalRADS.

Zoetis (NYSE: ZTS) has launched Portela® (relfovetmab) in Canada and European Union member states. According to Zoetis, Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody therapy for cats, providing up to three months of osteoarthritis (OA) pain relief from a single subcutaneous injection.

Backed by nearly a decade of research, Portela showed effectiveness in a pivotal nine-month European field study, with improvements observed from Day 3 after the first injection. Zoetis reports Portela was well tolerated in clinical trials and expands its feline OA pain portfolio alongside Solensia®, offering a less frequent, three‑month dosing option.

Zoetis (NYSE: ZTS) announced the launch of Lenivia (izenivetmab injection) in Canada and European Union member states. Lenivia is a long-acting monoclonal antibody therapy targeting nerve growth factor (NGF), designed to provide up to three months of osteoarthritis pain management for dogs with a single subcutaneous injection.

According to Zoetis, Lenivia showed sustained pain reduction from as early as Day 7 in a pivotal nine-month European field study. The product expands Zoetis’ osteoarthritis pain portfolio alongside Rimadyl, Trocoxil and Librela, supporting veterinarians and pet owners with an additional long-term pain management option for dogs.

Zoetis (NYSE:ZTS) announced an agreement to acquire VitalRADS, a veterinary teleradiology services platform, to strengthen its Global Diagnostics portfolio and advance an end-to-end Virtual Reference Lab. The acquisition builds on their August 2025 partnership and adds 24/7 cloud-based access to board-certified veterinary specialists across more than 25 species.

VitalRADS offers teleradiology, mobile ultrasound in Greater Houston and Greater Seattle, an outpatient imaging center in Cypress, Texas, and the VitalPACS cloud image storage platform. The business supports more than 1,800 active customers and is an American College of Veterinary Radiology certified residency program. Closing is expected in the third quarter of 2026, subject to customary conditions and regulatory approvals; financial terms were not disclosed.

Zoetis (NYSE:ZTS) received European Commission marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine for chickens.

The vaccine uses an HVT vector and in a single dose helps protect against Newcastle disease and Marek’s disease, administered in ovo or subcutaneously at hatch. Zoetis highlights benefits for EU poultry producers and export opportunities to southeast Asia.

Zoetis (NYSE:ZTS) will host a webcast and conference call to review its second quarter 2026 financial results at 8:30 a.m. ET on Thursday, August 6, 2026. CEO Kristin Peck and CFO Wetteny Joseph will discuss results and take analyst questions; webcast access and slides are via the Zoetis investor website, with replay available the same day.

Zoetis (NYSE:ZTS) released its 2025 Sustainability Report, showing progress under its Driven to Care strategy across Communities, Animals and Planet.

Highlights include $35 million in Zoetis Foundation grants from 2021–2025, 29% lower Scope 1 and 2 emissions since 2021, and 85% renewable electricity coverage in 2025.